The shares of this leading pharmaceutical company is in focus after shares worth Rs 879 crore exchanged hands via a block trade. In this article, we will discuss more about this deal.
With a market capitalization of Rs 12,334 crore, the shares of Zydus Wellness Ltd are currently trading at Rs 1,938 per share, down by 22 percent from its 52-week high of Rs 2,484 per share. Over the past five years, the stock has delivered a return of 53 percent.
On Tuesday, it is reported that shares worth Rs 879 crore exchanged hands via a block deal. The deal involved the exchange of 46.27 lakh shares (or 7.3 percent equity stake) at a floor price of Rs 1,900 per share, which is a discount of 0.73 percent from its previous day closing price. However, the buyer and seller is not yet known.
Financial Highlights
The company reported a revenue of Rs 2,709 crore in FY25, up by 16.36 percent from its FY24 revenue of Rs 2,328 crores. Additionally, it reported a net profit increase of 30 percent to Rs 347 crore in FY25 from Rs 267 crore in FY24.
The stock delivered an ROE and ROCE of 6.19 percent and 6.32 percent respectively, and is currently trading at a P/E of 36.12x as compared to its industry peers of 68.09x.
Zydus Wellness produces and sells health and wellness products in India, including key brands such as Sugar Free (sugar substitutes), Complan (health drink), Glucon-D (energy beverage), I’m Lite (stevia-based sugar), skincare under Everyuth, personal care under Nycil, and a range of spreads and dairy under Nutralite. It exports its products to other countries as well.
Written by Satyajeet Mukherjee
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
